Skip to main content

Tables 3 Metabolic status at the baseline and end of trial

From: Clinical and metabolic response to soy administration in older women with metabolic syndrome: a randomized controlled trial

Metabolic indicators

Baseline

End of trial

Soy-nut

TSP

Control

P value

Soy-nut

TSP

Control

P value

TC (mg/dl)

229.9 ± 5.13

229.4 ± 5.84

233.2 ± 5.20

0.87

200.7 ± 4.82a

205.2 ± 5.55a

224.5 ± 5.21

< 0.001

TG (mg/dl)

212.1 ± 8.23

211.9 ± 8.86

212.6 ± 10.65

0.99

199.8 ± 8.65

200.3 ± 9.09

208.5 ± 10.79

0.77

HDL-C (mg/dl)

44.2 ± 1.38

43.0 ± 0.98

44.2 ± 1.58

0.78

46.3 ± 1.17

44.8 ± 0.93

43.7 ± 1.71

0.35

LDL-C (mg/dl)

154.0 ± 3.28

154.7 ± 5.80

152.3 ± 6.01

0.95

131.0 ± 5.42a

134.5 ± 5.65

151.5 ± 6.51

< 0.05

VLDL-C (mg/dl)

41.7 ± 1.56

42.4 ± 1.77

42.4 ± 2.19

0.95

34.5 ± 1.83a

37.4 ± 2.03

42.0 ± 2.28

< 0.05

Apo AI (g/l)

1.8 ± 0.20

1.7 ± 0.22

1.6 ± 0.22

0.77

2.0 ± 0.19

1.9 ± 0.22

1.6 ± 0.21

0.31

Apo B100(g/l)

1.5 ± 0.09

1.5 ± 0.10

1.5 ± 0.17

0.96

1.2 ± 0.07a

1.2 ± 0.09

1.6 ± 0.16

< 0.05

FBG (mg/dl)

104.8 ± 2.01

104.3 ± 2.32

102.5 ± 2.49

0.75

90.4 ± 2.18a

97.8 ± 2.34

99.6 ± 2.83

< 0.05

Insulin (µIU/ml)

12.8 ± 0.79

11.6 ± 0.95

13.4 ± 0.9

0.36

10.8 ± 0.79a

10.8 ± 0.85a

13.8 ± 0.90

< 0.05

HOMA-IR

3.4 ± 0.25

3.0 ± 0.27

3.4 ± 0.25

0.51

2.5 ± 0.21a

2.6 ± 0.23

3.4 ± 0.24

< 0.01

TG/HDL

4.9 ± 0.27

5 ± 0.25

4.9 ± 0.34

0.99

4.41 ± 0.24

4.5 ± 0.24

5 ± 0.39

0.35

CRP (µg/ml)

3.2 ± 0.37

3.1 ± 0.45

3.0 ± 0.49

0.97

2.9 ± 0.38

3.0 ± 0.39

3.0 ± 0.33

0.98

Fibrinogen (mg/dl)

316.7 ± 6.89

316.5 ± 8.88

314.2 ± 9.37

0.97

297.8 ± 6.07

302.0 ± 6.37

306.4 ± 6.59

0.63

MDA (µmol/l)

4.9 ± 0.36

4.9 ± 0.17

5.3 ± 0.28

0.48

4.2 ± 0.35a

4.3 ± 0.19a

5.3 ± 0.25

< 0.001

TAC (µmol/l)

1302.0 ± 45.36

1305.3 ± 45.37

1305.1 ± 40.09

0.99

1516.3 ± 39.70a

1503.4 ± 35.28a

1350.2 ± 47.38

< 0.01

  1. TSP: Textured soy protein; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDL-C: high density lipoprotein; LDL-C: low density lipoprotein; VLDL-C: very low density lipoprotein; Apo AI: apolipoprotein AI; Apo B100: apolipoprotein B100; FBG: fasting blood glucose; HOMA-IR: homeostasis model of assessment insulin resistance; TG/HDL-C: triglyceride/high density lipoprotein; MDA: malondialdehyde; TAC: total antioxidant capacity; CRP: C-reactive protein
  2. Values are mean ± standard error
  3. aThere was a significant difference in the treatment groups compared with control group (post hoc ANOVA)